Gujarat Kidney FY26 profit rises, appoints auditors
Gujarat Kidney And Superspeciality Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026, showing a rise in standalone profit after tax to ₹990.14 lacs and consolidated profit after tax to ₹1,681.18 lacs. The board appointed internal and secretarial auditors and deferred the CEO appointment while seeking shareholder approval for a variation in its IPO objects via postal ballot.
*this image is generated using AI for illustrative purposes only.
Gujarat Kidney And Superspeciality Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026, on May 28, 2026. The board approved the results based on the recommendations of the Audit Committee, confirming that the auditor's reports are unmodified. The company also appointed internal and secretarial auditors and deferred the appointment of a Chief Executive Officer.
Financial Performance
For the full year ended March 31, 2026, the company reported a standalone profit after tax of ₹990.14 lacs, compared to ₹910.90 lacs in the previous year. Total standalone income rose to ₹4,059.47 lacs from ₹3,528.11 lacs in FY25. On a consolidated basis, profit after tax increased to ₹1,681.18 lacs from ₹949.94 lacs, with total income reaching ₹8,288.60 lacs.
The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The statutory auditor, M/s Y M Shah & Co., issued an unmodified report on the annual financial results and conducted a limited review of the quarterly results.
Key Appointments
The board appointed Mr Siddharth Atulbhai Shah as the Internal Auditor for FY 2026-27. Additionally, SPANJ & Associates was appointed as the Secretarial Auditor for a period of five consecutive years from 2026-27 to 2030-31, subject to shareholder approval at the ensuing Annual General Meeting.
Corporate Actions
The company will conduct a postal ballot to seek shareholder approval for a variation in the objects of its Initial Public Offering (IPO) via special resolution. The agenda for the appointment of a Chief Executive Officer was deferred by the board.
| Metric | Standalone FY26 | Standalone FY25 |
|---|---|---|
| Total Income | ₹4,059.47 lacs | ₹3,528.11 lacs |
| Profit After Tax | ₹990.14 lacs | ₹910.90 lacs |
| Earnings Per Share (Basic) | ₹1.59 | ₹1.79 |
Historical Stock Returns for Gujarat Kidney and Super Speciality
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.29% | -0.78% | -8.55% | +24.43% | +24.43% | +24.43% |
What specific changes to the IPO objects are proposed, and how will they impact the company's capital allocation strategy?
When does the board expect to finalize the appointment of a Chief Executive Officer, and what criteria are being prioritized?
What factors drove the significant divergence between standalone and consolidated profit growth in FY26?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
